Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.

@article{Costa2016SpotlightOL,
  title={Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.},
  author={Ricardo L B Costa and Benedito A. Carneiro and Sunandana Chandra and Sachin Gopalkrishna Pai and Young Kwang Chae and Jason Benjamin Kaplan and Hannah B Garrett and Mark Agulnik and Peter Andreas Kopp and Francis J Giles},
  journal={Drug design, development and therapy},
  year={2016},
  volume={10},
  pages={873-84}
}
Thyroid cancer is the most common endocrine malignancy, with over 60,000 cases reported per year in the US alone. The incidence of thyroid cancer has increased in the last several years. Patients with metastatic differentiated thyroid cancer (DTC) generally have a good prognosis. Metastatic DTC can often be treated in a targeted manner with radioactive iodine, but the ability to accumulate iodine is lost with decreasing differentiation. Until recently, chemotherapy was the only treatment in… CONTINUE READING